AstraZeneca Announces Opening of New South San Francisco Site

Employees from four AstraZeneca organizations co-locate under one roof, providing new opportunities for scientific innovation and collaboration
 

AstraZeneca today announced the official opening of its new South San Francisco location.  Bay Area employees from Acerta Pharma, MedImmune, Pearl Therapeutics and AstraZeneca’s TIDE (Technology Innovation & Delivery Excellence) are now located at a single state-of-the-art facility in the Cove at Oyster Point, in the heart of the area’s vibrant biotechnology and technology community.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, said: “The opening of our South San Francisco site is a milestone for AstraZeneca, enabling talent from four organizations to work side-by-side at the center of where biotechnology and high-tech industry intersects.  This is a demonstration of our commitment to a strong and visible presence in California, our continued growth through science- and collaboration-led innovation, and our dedication to being a great place to work for current and future employees.”

Custom-designed to encourage collaboration and spark scientific innovation, the site’s facilities are equipped with cutting-edge open lab space and an office environment that incorporates AstraZeneca’s iWork philosophy, an activity-based working approach that embraces industry best practices.

Additional highlights of the purpose-built site include:

  • Building and lab space that reflects AstraZeneca’s commitment to minimizing the environmental footprint of our products and processes
  • Cutting-edge open and agile lab design, including windows into labs from public spaces to see science in action
  • Design and architecture by HOK, a global design, architecture, engineering and planning firm with expertise in the design of sustainable biotech facilities
  • Focus on health and safety for employees, with on-site pantries offering organic foods, adjustable desks and ergo dynamic chairs, treadmill-equipped team rooms, and an on-campus gym

Bahija Jallal, President of MedImmune and Executive Vice President of AstraZeneca, said: “Collaboration is at the core of our culture and a key driver of innovation.  The opening of our new South San Francisco site brings together the best of both worlds -- a shared drive across our employee base to advance great science and bring new treatments to patients, while providing an opportunity to tap into the Bay Area’s transformative biotech ecosystem, helping to foster great progress internally and externally.”

NOTES TO EDITORS

About MedImmune
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular, Renal and Metabolic Diseases, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK and South San Francisco, CA. For more information, please visit www.medimmune.com.

About Acerta Pharma
Acerta Pharma, a member of the AstraZeneca Group, is creating novel therapies intended for the treatment of cancer.  AstraZeneca acquired a majority stake interest in Acerta Pharma, which serves as AstraZeneca’s hematology research and development center of excellence.  For more information, please visit www.acertapharma.com.

About Pearl Therapeutics
Pearl Therapeutics was founded in 2006, with a mission and vision to develop differentiated therapeutics for widely prevalent respiratory disease conditions, including chronic obstructive pulmonary disease (COPD), by utilizing a proprietary drug delivery platform and existing therapeutic agents administered in metered-dose inhalers (MDIs).  In 2013, AstraZeneca acquired Pearl to expand and strengthen its respiratory products portfolio, which includes many Pearl legacy compounds, and have made strides in bringing therapies to asthma patients.  For more information, please visit www.astrazeneca.com/our-focus-areas/pearl-therapeutics.html.

About TIDE (Technology Innovation & Delivery Excellence)
TIDE (Technology Innovation & Delivery Excellence) is committed to bringing Silicon Valley technology and innovation to AstraZeneca.  They contribute to technology strategy, partnering in emerging areas, including: sensors, mobile health, AI, and new user interfaces. They also bring mobile and cloud software engineering, data analytics and machine learning capabilities which contribute to our digital initiatives.

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory.  The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit: www.astrazeneca.com and follow us on Twitter @AstraZeneca

CONTACTS

Media Relations

 

 

Tracy Rossin

US

+1 301 398 1468

Michele Meixell

US

+1 302 885 2677

Gonzalo Viña

UK/Global

+44 203 749 5916

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Jacob Lund

Sweden

+46 8 553 260 20

 

Investor Relations

 

 

Thomas Kudsk Larsen

 

 

+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Henry Wheeler

Oncology

+44 203 749 5797

Mitchell Chan

Oncology; Other

+1 240 477 3771

Christer Gruvris

Brilinta; Diabetes

+44 203 749 5711

Nick Stone

Respiratory; Renal

+44 203 749 5716

US toll free

 

+1 866 381 7277